Author: admin

“Psychosis in Parkinson’s and Alzheimer’s Disease Market”

Emerging therapies for psychosis in Parkinson’s and Alzheimer’s disease, including NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others, are expected to drive significant growth in the market in the coming years.

DelveInsight has launched a new report on “Psychosis in Parkinson’s and Alzheimer’s Disease – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Psychosis in Parkinson’s and Alzheimer’s Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson’s and Alzheimer’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report:

• According to DelveInsight, the psychosis market in Parkinson’s disease and Alzheimer’s disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023 and is expected to grow steadily over the forecast period from 2024 to 2034.

• In 2023, the total number of diagnosed Parkinson’s disease cases in the 7MM was estimated at 2.6 million, with the United States accounting for about 45% of these cases. The EU4 (France, Germany, Italy, and Spain) and the UK together also represented roughly 45%, while Japan contributed around 10%. The prevalence of Parkinson’s disease is projected to rise by 2034.

• During the same year, an estimated 6.9 million diagnosed cases of psychosis associated with Parkinson’s and Alzheimer’s disease were reported in the 7MM. Among these, the United States accounted for 34%, Japan nearly 31%, and Germany around 11%.

• The market for psychosis in these neurodegenerative diseases is expected to expand, driven by the launch of innovative therapies. Key emerging treatments include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and ITI-1284 by Intra-Cellular Therapies.

• With the aging population growing, the prevalence of Parkinson’s and Alzheimer’s disease is expected to increase, fueling demand for effective psychosis treatments. Greater awareness of psychosis as a significant symptom may lead to earlier diagnosis and better management, further supporting market growth.

• However, substantial unmet needs remain. The lack of curative therapies and reliable biomarkers makes early diagnosis and treatment challenging. Existing screening tools are often complex, and while NUPLAZID (pimavanserin) is approved for psychosis in Parkinson’s disease, there is no FDA-approved treatment for psychosis in Alzheimer’s disease, highlighting a critical gap. Additionally, psychosis symptoms are often underreported or misattributed, causing delays in care and inaccuracies in epidemiological data.

• Key companies actively developing therapies in this space include Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others. Promising pipeline candidates include NUPLAZID, Ulotaront, KarXT, ITI-1284, among others.

• In May 2023, the FDA approved Rexulti (brexpiprazole) for treating agitation associated with dementia due to Alzheimer’s disease. This marked the first FDA-approved therapy addressing restlessness and aggression in Alzheimer’s patients. Clinical trials showed that patients receiving 2 mg or 3 mg of Rexulti experienced significant symptom improvements compared to placebo, with common side effects including headache, dizziness, urinary tract infections, and sleep disturbances.

Key benefits of the Psychosis in Parkinson’s and Alzheimer’s Disease market report:

1. Psychosis in Parkinson’s and Alzheimer’s Disease market report covers a descriptive overview and comprehensive insight of the Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology and Psychosis in Parkinson’s and Alzheimer’s Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Psychosis in Parkinson’s and Alzheimer’s Disease market report provides insights on the current and emerging therapies.

3. Psychosis in Parkinson’s and Alzheimer’s Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Psychosis in Parkinson’s and Alzheimer’s Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psychosis in Parkinson’s and Alzheimer’s Disease market.

Got queries? Click here to know more about the Psychosis in Parkinson’s and Alzheimer’s Disease Market Landscape.

Psychosis in Parkinson’s and Alzheimer’s Disease Overview

According to the National Institute of Mental Health (NIMH), psychosis is a group of symptoms that interfere with an individual’s perception of reality, causing a disconnection from the real world. During a psychotic episode, a person’s thoughts and perceptions are distorted, making it difficult to differentiate between what is real and what is not.

Psychosis is generally divided into three main types: idiopathic psychosis, psychosis resulting from medical conditions (such as neurodegenerative disorders), and toxic psychosis, which arises from substance use, medications, or exposure to toxins. It is a symptom complex that can occur in various disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), where severe psychotic manifestations may develop.

In Parkinson’s disease psychosis (PDP), patients often experience visual hallucinations, along with other symptoms such as auditory hallucinations, delusions, illusions, depression, and anxiety. PDP is linked to higher morbidity and mortality, decreased engagement in health-promoting behaviors, and an increased risk of long-term care placement. Similarly, Alzheimer’s disease psychosis (ADP) frequently occurs in individuals with AD, presenting with dementia, auditory and visual hallucinations, and progressive cognitive decline. These symptoms worsen over time, substantially affecting both life expectancy and quality of life.

Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook

Psychosis frequently occurs in individuals with Alzheimer’s disease and often persists throughout the course of the illness. Studies indicate that over half of Alzheimer’s patients will experience psychotic symptoms at some point during their disease progression.

Antipsychotic medications remain the primary treatment for managing psychotic episodes, with drug choice, dosage, and administration tailored to the specific condition. Alongside pharmacological therapy, caregivers and family members play a vital role in managing psychosis by providing a safe and supportive environment. Cognitive behavioral therapy (CBT) is also commonly recommended as an initial intervention for individuals exhibiting psychotic symptoms.

Although standardized treatment guidelines are limited, pimavanserin (34 mg/day) is considered first-line therapy for Parkinson’s disease psychosis, as it is the only FDA-approved drug for this condition and has a low risk of severe adverse effects. If pimavanserin is unavailable or ineffective, clozapine (up to 50 mg/day) or quetiapine (titrated up to 150 mg/day) may be used. However, quetiapine may not fully control psychotic symptoms in some patients, while clozapine carries the risk of agranulocytosis and requires regular blood monitoring.

There is a pressing need for more effective and targeted therapies for psychosis in both Alzheimer’s and Parkinson’s disease, as current treatments are often limited by side effects such as hallucinations, confusion, and nausea. With no FDA-approved therapy for Alzheimer’s disease psychosis, developing precise risk profiles and optimizing the use of existing antipsychotics remain critical objectives.

To address these unmet needs, several late-stage drug candidates are under development. These include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and FANAPT (iloperidone), all of which show promise in expanding treatment options for psychosis associated with neurodegenerative diseases.

Psychosis in Parkinson’s and Alzheimer’s Disease Marketed Drugs

• NUPLAZID (pimavanserin): Acadia Pharmaceuticals

Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Drugs

• Ulotaront (SEP-363856): Sunovion Pharmaceuticals

• KarXT (xanomeline-trospium): Karuna Therapeutics

• ITI-1284: Intra-Cellular Therapies

Scope of the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Psychosis in Parkinson’s and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others

• Key Psychosis in Parkinson’s and Alzheimer’s Disease Therapies: NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others

• Psychosis in Parkinson’s and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s and Alzheimer’s Disease current marketed and Psychosis in Parkinson’s and Alzheimer’s Disease emerging therapies

• Psychosis in Parkinson’s and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s and Alzheimer’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Psychosis in Parkinson’s and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s and Alzheimer’s Disease Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Psychosis in Parkinson’s and Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Psychosis in Parkinson’s and Alzheimer’s Disease Market Overview at a Glance

6. Psychosis in Parkinson’s and Alzheimer’s Disease Disease Background and Overview

7. Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Psychosis in Parkinson’s and Alzheimer’s Disease

9. Psychosis in Parkinson’s and Alzheimer’s Disease Current Treatment and Medical Practices

10. Unmet Needs

11. Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Therapies

12. Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook

13. Country-Wise Psychosis in Parkinson’s and Alzheimer’s Disease Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Psychosis in Parkinson’s and Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook 2034.

Related Reports:

Psychosis in Parkinson’s and Alzheimer’s Disease Pipeline Insights, DelveInsight

“Psychosis in Parkinson’s and Alzheimer’s Disease Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psychosis in Parkinson’s and Alzheimer’s Disease market. A detailed picture of the Psychosis in Parkinson’s and Alzheimer’s Disease pipeline landscape is provided, which includes the disease overview and Psychosis in Parkinson’s and Alzheimer’s Disease treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psychosis in Parkinson’s and Alzheimer’s Disease Market: Epidemiology, Pipeline Products, Companies, DelveInsight | Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Phar

“Focal Epilepsy Market”

Focal Epilepsy therapies are expected to boost the Focal Epilepsy Market in the upcoming years.

DelveInsight has launched a new report on “Focal Epilepsy – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Focal Epilepsy, historical and forecasted epidemiology as well as the Focal Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for sample pages @ https://www.delveinsight.com/report-store/focal-epilepsy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Focal Epilepsy Market Report:

The Focal Epilepsy Market has made notable progress in recent years, driven by an improved understanding of disease mechanisms, the emergence of new treatment options, and ongoing research into innovative therapies.

Key players in this market include Biocodex, Biohaven Therapeutics, Xenon Pharmaceuticals, UCB Pharma, SK Life Science, Jazz Pharmaceuticals, Vertex Pharmaceuticals, Supernus Pharmaceuticals, Neurocrine Biosciences, and others, all actively working to advance treatment solutions for focal epilepsy.

In March 2025, several important developments occurred in the market:

• Biohaven Therapeutics launched a study to evaluate the efficacy of BHV-7000 in patients with refractory focal epilepsy.

• Eisai Korea initiated a study to assess perampanel monotherapy, measuring seizure-free rates over a 24-week maintenance period in untreated participants with focal onset seizures, with or without focal to bilateral tonic-clonic seizures.

• Rapport Therapeutics conducted clinical trials on RAP-219 in patients with refractory focal epilepsy to evaluate its safety and efficacy.

• Xenon Pharmaceuticals announced the X-TOLE2 Phase 3 trial, a randomized, double-blind, placebo-controlled study assessing the efficacy, safety, and tolerability of XEN1101 as an adjunctive therapy for focal-onset seizures.

Key benefits of the Focal Epilepsy market report:

1. Focal Epilepsy market report covers a descriptive overview and comprehensive insight of the Focal Epilepsy Epidemiology and Focal Epilepsy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Focal Epilepsy market report provides insights on the current and emerging therapies.

3. Focal Epilepsy market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Focal Epilepsy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Focal Epilepsy market.

Got queries? Click here to know more about the Focal Epilepsy Market Landscape

Focal Epilepsy Overview

Focal epilepsy is a neurological disorder marked by seizures that begin in a specific region of the brain. These seizures may stay confined to that area or spread to other parts, causing symptoms that vary depending on the affected region. Unlike generalized epilepsy, which impacts both hemispheres of the brain at once, focal epilepsy originates in a single location and can influence motor skills, sensory perception, or consciousness in diverse ways.

Focal Epilepsy Market Outlook

The Focal Epilepsy market is projected to undergo substantial growth in the coming years, fueled by the anticipated launch of innovative therapies from key players, including Biocodex, Biohaven Therapeutics, Xenon Pharmaceuticals, UCB Pharma, SK Life Science, Jazz Pharmaceuticals, Vertex Pharmaceuticals, Supernus Pharmaceuticals, Neurocrine Biosciences, and others, over the forecast period from 2020 to 2034.

Discover how the focal epilepsy market is rising in the upcoming years

Focal Epilepsy Key Companies: Biocodex, Biohaven Therapeutics Ltd., Xenon Pharmaceuticals Inc., UCB Pharma, SK Life Science Inc., Jazz Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Supernus Pharmaceuticals Inc., Neurocrine Biosciences, and others.

Scope of the Focal Epilepsy Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Focal Epilepsy Companies: Biocodex, Biohaven Therapeutics Ltd., Xenon Pharmaceuticals Inc., UCB Pharma, SK Life Science Inc., Jazz Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Supernus Pharmaceuticals Inc., Neurocrine Biosciences, and others

• Focal Epilepsy Therapeutic Assessment: Focal Epilepsy current marketed and Focal Epilepsy emerging therapies

• Focal Epilepsy Market Dynamics: Focal Epilepsy market drivers and Focal Epilepsy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Focal Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Focal Epilepsy Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Focal Epilepsy Patient Share (%) Overview at a Glance

5. Focal Epilepsy Market Overview at a Glance

6. Focal Epilepsy Disease Background and Overview

7. Focal Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Focal Epilepsy

9. Focal Epilepsy Current Treatment and Medical Practices

10. Unmet Needs

11. Focal Epilepsy Emerging Therapies

12. Focal Epilepsy Market Outlook

13. Country-Wise Focal Epilepsy Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Focal Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Focal Epilepsy Market Outlook 2034

Related Reports:

Focal Epilepsy Pipeline Insights, DelveInsight

“Focal Epilepsy Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Focal Epilepsy market. A detailed picture of the Focal Epilepsy pipeline landscape is provided, which includes the disease overview and Focal Epilepsy treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Focal Epilepsy Market: Epidemiology, Pipeline, Companies, DelveInsight | Biocodex, Biohaven Therapeutics Ltd., Xenon Pharmaceuticals Inc., UCB Pharma, SK Life Science Inc., Jazz Pharmaceuticals, Verte

“Alzheimer’s Disease Clinical Trials”

DelveInsight’s analysis highlights that the Alzheimer’s Disease pipeline comprises over 110 key companies actively engaged in developing more than 120 treatment therapies.

Alzheimer’s Disease Overview:

Alzheimer’s disease (AD) is a neurodegenerative disorder that causes the progressive deterioration of brain cells and is the leading cause of dementia, characterized by cognitive decline and the loss of independence in daily life. AD is considered a multifactorial condition, with two primary hypotheses proposed for its development: the cholinergic hypothesis and the amyloid hypothesis. Several risk factors also contribute to its onset, including aging, genetic predisposition, head trauma, vascular conditions, infections, and environmental influences.

The symptoms of Alzheimer’s disease vary with disease stage. Based on the severity of cognitive decline, AD is categorized into preclinical (presymptomatic), mild, and dementia-stage, which differ from the DSM-5 classification of the condition.

The earliest and most common symptom is episodic short-term memory loss, while long-term memory is often preserved in the early stages. As the disease progresses, patients may experience difficulties with problem-solving, judgment, executive functioning, and motivation, leading to issues with multitasking and abstract thinking. Executive dysfunction in the early phase may range from mild to severe.

Request for a detailed insights report on Alzheimer’s Disease pipeline insights

“Alzheimer’s Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer’s Disease Therapeutics Market.

Key Takeaways from the Alzheimer’s Disease Pipeline Report

• DelveInsight’s Alzheimer’s Disease pipeline report highlights a dynamic landscape, featuring over 110 active companies developing more than 120 therapeutic candidates for Alzheimer’s treatment. Leading industry players, including AriBio, Eli Lilly, Cognition Therapeutics, AbbVie, Allyx Therapeutics, Cassava Sciences, BioVie, Novo Nordisk, Alector, Longeveron, TrueBinding, VT BIO, Luye Pharma, Lexeo Therapeutics, Merck, Regeneration Biomedical, Alnylam, Sinotau Pharmaceutical, Eisai, Shanghai Hengrui, and others, are advancing novel therapies to enhance the treatment paradigm.

• Notable pipeline candidates in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and more.

• In July 2024, the U.S. FDA approved Kisunla™ (donanemab-azbt) for adults with early symptomatic Alzheimer’s disease. Clinical studies demonstrated a 35% reduction in cognitive and functional decline over 18 months compared to placebo and a 39% lower risk of progression to the next disease stage. Kisunla is notable for its limited-duration treatment regimen, with nearly half of the study participants completing the course within 12 months.

Alzheimer’s Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Alzheimer’s Disease Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer’s Disease market.

Download our free sample page report on Alzheimer’s Disease pipeline insights

Alzheimer’s Disease Emerging Drugs

• AR1001: AriBio Co., Ltd.

• NE3107: BioVie

• LY3372689: Eli Lilly & Co.

• CT1812: Cognition Therapeutics

• ABBV-916: AbbVie Inc.

• ALX-001: Allyx Therapeutics, Inc.

Alzheimer’s Disease Companies

Over 110 leading companies are currently working on developing therapies for Alzheimer’s disease, with AriBio Co., Ltd. and BioVie having candidates in the most advanced stage, currently in Phase III clinical trials.

DelveInsight’s report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Alzheimer’s Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer’s Disease Therapies and Key Companies: Alzheimer’s Disease Clinical Trials and advancements

Alzheimer’s Disease Pipeline Therapeutic Assessment

• Alzheimer’s Disease Assessment by Product Type

• Alzheimer’s Disease By Stage

• Alzheimer’s Disease Assessment by Route of Administration

• Alzheimer’s Disease Assessment by Molecule Type

Download Alzheimer’s Disease Sample report to know in detail about the Alzheimer’s Disease treatment market @ Alzheimer’s Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Alzheimer’s Disease Current Treatment Patterns

4. Alzheimer’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alzheimer’s Disease Late-Stage Products (Phase-III)

7. Alzheimer’s Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alzheimer’s Disease Discontinued Products

13. Alzheimer’s Disease Product Profiles

14. Alzheimer’s Disease Key Companies

15. Alzheimer’s Disease Key Products

16. Dormant and Discontinued Products

17. Alzheimer’s Disease Unmet Needs

18. Alzheimer’s Disease Future Perspectives

19. Alzheimer’s Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Alzheimer’s Disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alzheimer’s Disease Clinical Trials, Companies, Therapeutic Assessment, Emerging, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeu

“Agitation in Alzheimer’s Disease Market”

Emerging therapies for Agitation in Alzheimer’s Disease, including TransCon hGH, HyTropin (GX-H9), Somatrogon, and others, are anticipated to drive significant growth in the market over the coming years.

DelveInsight has launched a new report on “Agitation in Alzheimer’s Disease – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Agitation in Alzheimer’s Disease, historical and forecasted epidemiology as well as the Agitation in Alzheimer’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our sample pages @ https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Agitation in Alzheimer’s Disease Market Report:

• In Europe, the prevalence of agitation among Alzheimer’s patients has been reported to range between 24% and 88%, with nearly half of the studies (47%) indicating rates of 50% or higher.

• The Agitation in Alzheimer’s Disease market is projected to grow at a steady CAGR from 2024 to 2034, largely driven by the rising aging population, especially in developed nations where Alzheimer’s prevalence is higher. With increasing life expectancy, the number of individuals affected by Alzheimer’s and associated symptoms like agitation is expected to rise significantly.

• Epidemiological data highlights agitation as a common manifestation in Alzheimer’s disease, though prevalence varies due to differences in diagnostic criteria and study methodologies. It is estimated that up to 50% of Alzheimer’s patients experience agitation at some point during their illness.

• Management of agitation in Alzheimer’s disease continues to pose major challenges due to the lack of early detection tools, targeted therapies, and curative options. Currently, REXULTI (brexpiprazole) remains the only FDA-approved treatment specifically indicated for agitation associated with Alzheimer’s-related dementia.

• Several pharmaceutical companies are actively pursuing new therapeutic options. Key players such as Johnson & Johnson, Otsuka, IGC Pharma, and BioXcel are advancing promising candidates, including AXS-05 (Axsome Therapeutics), AVP-786 (Otsuka), and IGC-AD1 (IGC Pharma), which are anticipated to enter the market within the forecast period and reshape the treatment landscape.

• In March 2025, BioXcel Therapeutics, Inc. reported that the U.S. FDA had completed the inspection of a trial site involved in its TRANQUILITY II Phase 3 study under 21 C.F.R. 20.64(d)(3), issuing the Establishment Inspection Report.

Key benefits of the Agitation in Alzheimer’s Disease market report:

1. Agitation in Alzheimer’s Disease market report covers a descriptive overview and comprehensive insight of the Agitation in Alzheimer’s Disease Epidemiology and Agitation in Alzheimer’s Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Agitation in Alzheimer’s Disease market report provides insights on the current and emerging therapies.

3. Agitation in Alzheimer’s Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Agitation in Alzheimer’s Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Agitation in Alzheimer’s Disease market.

Got queries? Click here to know more about the Agitation in Alzheimer’s Disease Market Landscape

Agitation in Alzheimer’s Disease Overview

As Alzheimer’s disease advances, many individuals develop symptoms of agitation or aggression. Agitation is characterized by restlessness and anxiety, making it difficult for the person to stay calm. This may present as pacing, sleep disturbances, or aggressive behaviors such as verbal outbursts or attempts to cause harm. Consequently, agitation is one of the most common and distressing symptoms of Alzheimer’s, often leading to disruptive behavior.

Managing agitation in Alzheimer’s is challenging due to its multifactorial origins. Biological factors such as neurotransmitter imbalances and structural brain changes play a significant role, while medical issues including pain, infections, sleep problems, confusion, and side effects from medications can further aggravate symptoms. Additionally, psychological stressors like fear or perceived threats often act as triggers.

Both patients and caregivers often require comprehensive support to cope with agitation and aggression. While non-pharmacological interventions can be effective, targeted medications and therapeutic strategies are also used to ease symptoms and enhance overall quality of life.

Agitation in Alzheimer’s Disease Market Outlook

The primary goal in treating agitation associated with Alzheimer’s disease is to manage symptoms and improve patients’ overall well-being. Current strategies often rely on antipsychotic medications such as risperidone and quetiapine; however, these drugs are linked to risks including sedation, metabolic complications, and a higher risk of strokes in older adults. Alongside medications, non-pharmacological interventions like music therapy, aromatherapy, and structured daily routines play an important role in reducing aggression and offering safer alternatives.

Most drug therapies for agitation in Alzheimer’s target dopamine and serotonin receptors to help alleviate behavioral disturbances. Therefore, effective management typically combines both pharmacological and non-pharmacological approaches within a comprehensive care plan.

Commonly prescribed medications include risperidone, quetiapine, aripiprazole, carbamazepine, citalopram, gabapentin, prazosin, trazodone, lorazepam, and cyproterone acetate. While these treatments may help control symptoms, they also pose risks such as falls, sedation, and metabolic side effects.

Currently, REXULTI (brexpiprazole) is the only FDA-approved therapy for agitation linked to Alzheimer’s dementia. It works through a multimodal mechanism—acting as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors—helping regulate mood and behavior more effectively.

Discover how the Alzheimer’s disease market is rising

Agitation in Alzheimer’s Disease Marketed Drugs

• REXULTI (brexpiprazole): Otsuka Pharmaceuticals

Agitation in Alzheimer’s Disease Emerging Drugs

• AXS-05: Axsome Therapeutics

• AVP-786: Otsuka Pharmaceutical Development & Commercialization

• BXCL501: BioXcel Therapeutics

Scope of the Agitation in Alzheimer’s Disease Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Agitation in Alzheimer’s Disease Companies: Eli Lilly and Co, BioVie Inc, AB Science SA, Annovis Bio Inc, Cognition Therapeutics Inc, Coya Therapeutics Inc, Actinogen Medical Limited, AC Immune SA, Biogen Inc, Longeveron Inc, and others

• Agitation in Alzheimer’s Disease Therapeutic Assessment: Agitation in Alzheimer’s Disease current marketed and Agitation in Alzheimer’s Disease emerging therapies

• Agitation in Alzheimer’s Disease Market Dynamics: Agitation in Alzheimer’s Disease market drivers and Agitation in Alzheimer’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Agitation in Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Agitation in Alzheimer’s Disease Market Access and Reimbursement

Request for sample pages @ https://www.delveinsight.com/sample-request/agitation-in-alzheimer-disease?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Agitation in Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Agitation in Alzheimer’s Disease Market Overview at a Glance

6. Agitation in Alzheimer’s Disease Disease Background and Overview

7. Agitation in Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Agitation in Alzheimer’s Disease

9. Agitation in Alzheimer’s Disease Current Treatment and Medical Practices

10. Unmet Needs

11. Agitation in Alzheimer’s Disease Emerging Therapies

12. Agitation in Alzheimer’s Disease Market Outlook

13. Country-Wise Agitation in Alzheimer’s Disease Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Agitation in Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Agitation in Alzheimer’s Disease Market Outlook 2034

Related Reports:

Agitation in Alzheimer’s Disease Pipeline Insights, DelveInsight

“Agitation in Alzheimer’s Disease Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Agitation in Alzheimer’s Disease market. A detailed picture of the Agitation in Alzheimer’s Disease pipeline landscape is provided, which includes the disease overview and Agitation in Alzheimer’s Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Agitation in Alzheimer’s Disease Market: Epidemiology, Pipeline, Companies Working, DelveInsight | Eli Lilly and Co, BioVie Inc, AB Science SA, Annovis Bio Inc, Cognition Therapeutics Inc, Coya Therap

“Diabetic Neuropathy Clinical Trials”

According to DelveInsight, the Diabetic Neuropathy pipeline includes over 20 key companies actively developing more than 25 therapeutic candidates for the treatment of diabetic neuropathy.

Diabetic Neuropathy Overview:

Diabetic neuropathy is a type of nerve damage that occurs in individuals with diabetes, particularly those with long-term poor blood sugar control. It mainly affects the peripheral nerves, which control sensation and movement in the limbs. Diabetic neuropathy can manifest in several forms, including peripheral neuropathy (impacting hands and feet), autonomic neuropathy (affecting internal organs), proximal neuropathy (causing pain in the thighs, hips, or buttocks), and focal neuropathy (targeting a specific nerve).

Symptoms vary depending on the type and extent of nerve damage. Peripheral neuropathy often presents as tingling, numbness, or pain in the extremities, which may worsen over time, potentially leading to loss of sensation and motor difficulties. Autonomic neuropathy can cause digestive issues, urinary problems, and cardiovascular complications. Proximal neuropathy typically causes pain in the thighs, hips, or buttocks, whereas focal neuropathy results in sudden, localized pain or weakness in a particular nerve.

Request for a detailed insights report on Diabetic Neuropathy pipeline insights

“Diabetic Neuropathy Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetic Neuropathy Therapeutics Market.

Key Takeaways from the Diabetic Neuropathy Pipeline Report

• DelveInsight’s Diabetic Neuropathy pipeline report highlights a vibrant landscape, featuring over 20 active companies developing more than 25 therapeutic candidates for the treatment of diabetic neuropathy.

• Leading companies, including Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Teijin America, Shanghai Pharmaceuticals, ChemoCentryx, Roche, Cyclerion Therapeutics, Inversago Pharma, Sunshine Lake Pharma, Goldfinch Bio, Cosette Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, and others, are actively evaluating novel therapies to enhance the management of diabetic neuropathy.

• Notable pipeline candidates in various stages of development include SER 150, LMB-763, CU01, among others.

• In January 2024, Neuralace Medical received FDA clearance for Axon Therapy, a non-invasive magnetic peripheral nerve stimulation (mPNS) treatment for chronic painful diabetic neuropathy (PDN). This therapy delivers painless magnetic pulses in 13.5-minute sessions, representing a novel approach to pain management. Clinical evaluation through a double-blind, multicenter randomized controlled trial demonstrated a 72.3% responder rate and a 57.6% average reduction in pain scores at 30 days, with responder rates rising to 81.4% in the treatment group by 90 days.

Diabetic Neuropathy Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Diabetic Neuropathy Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Neuropathy treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetic Neuropathy market.

Download our free sample page report on Diabetic Neuropathy pipeline insights

Diabetic Neuropathy Emerging Drugs

• SER 150: Serodus

• LMB-763: Novartis

• CU01: Curacle Co., Ltd

Diabetic Neuropathy Companies

Over 20 leading companies are actively working on therapies for diabetic neuropathy, with Serodus having a candidate in the most advanced stage, currently progressing through Phase II/III clinical trials.

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Diabetic Neuropathy Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Diabetic Neuropathy Therapies and Key Companies: Diabetic Neuropathy Clinical Trials and advancements

Diabetic Neuropathy Pipeline Therapeutic Assessment

• Diabetic Neuropathy Assessment by Product Type

• Diabetic Neuropathy By Stage

• Diabetic Neuropathy Assessment by Route of Administration

• Diabetic Neuropathy Assessment by Molecule Type

Download Diabetic Neuropathy Sample report to know in detail about the Diabetic Neuropathy treatment market @ Diabetic Neuropathy Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Diabetic Neuropathy Current Treatment Patterns

4. Diabetic Neuropathy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diabetic Neuropathy Late-Stage Products (Phase-III)

7. Diabetic Neuropathy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetic Neuropathy Discontinued Products

13. Diabetic Neuropathy Product Profiles

14. Diabetic Neuropathy Key Companies

15. Diabetic Neuropathy Key Products

16. Dormant and Discontinued Products

17. Diabetic Neuropathy Unmet Needs

18. Diabetic Neuropathy Future Perspectives

19. Diabetic Neuropathy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Diabetic Neuropathy Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Neuropathy Clinical Trials, Companies, Therapies, Therapies, Pipeline Analysis | Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceutic

“Chronic Pain Associated with Painful Diabetic Neuropathy Market”

The emergence of new therapies for Chronic Pain Associated with Painful Diabetic Neuropathy is anticipated to drive significant growth in the market over the coming years.

DelveInsight has launched a new report on “Chronic Pain Associated with Painful Diabetic Neuropathy – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Chronic Pain Associated with Painful Diabetic Neuropathy, historical and forecasted epidemiology as well as the Chronic Pain Associated with Painful Diabetic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download sample pages on our chronic pain associated with painful diabetic neuropathy market

Some of the key facts of the Chronic Pain Associated with Painful Diabetic Neuropathy Market Report:

• According to DelveInsight, the Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) market is expected to experience steady growth between 2023 and 2034, fueled by the introduction of novel therapies and the rising prevalence of cases. Key players such as AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., and Erchonia Corporation are actively developing treatments within this space.

• The National Health Service reports that roughly 21–25% of people with diabetes in the UK suffer from painful diabetic neuropathy. While the development pipeline for PDN-related chronic pain remains relatively limited, several promising therapies are progressing toward commercialization. These include MEDI7352 (AstraZeneca), Ricolinostat (Regenacy Pharmaceuticals), SCS HF10 Technology (Nevro Corp.), and Erchonia® EVRL™ (Erchonia Corporation).

• In 2022, the FDA approved spinal cord stimulation (SCS) devices for managing chronic, intractable pain associated with PDN. Notably, the Vanta™ system delivers low-frequency stimulation with a battery life of approximately 11 years, while the Intellis™ system offers high-frequency stimulation with transcutaneous recharge capability within an hour.

• Earlier, in July 2021, the FDA approved Nevro’s 10 kHz high-frequency SCS therapy for PDN, following the SENZA-PDN randomized controlled trial, which demonstrated significant pain relief and improvements in patients’ quality of life.

• These advancements signal a growing focus on both pharmacological and device-based interventions, which are poised to reshape the treatment landscape for chronic pain in PDN.

Key benefits of the Chronic Pain Associated with Painful Diabetic Neuropathy market report:

1. Chronic Pain Associated with Painful Diabetic Neuropathy market report covers a descriptive overview and comprehensive insight of the Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology and Chronic Pain Associated with Painful Diabetic Neuropathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Chronic Pain Associated with Painful Diabetic Neuropathy market report provides insights on the current and emerging therapies.

3. Chronic Pain Associated with Painful Diabetic Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Chronic Pain Associated with Painful Diabetic Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Pain Associated with Painful Diabetic Neuropathy market.

Got queries? Click here to know more about the Chronic Pain Associated with Painful Diabetic Neuropathy Market Landscape

Chronic Pain Associated with Painful Diabetic Neuropathy Overview

Chronic pain associated with Painful Diabetic Neuropathy (PDN) is a debilitating condition impacting millions globally. As a serious complication of diabetes, it substantially diminishes patients’ quality of life. The condition arises from nerve damage, primarily affecting the peripheral nervous system, and leads to persistent pain, most often in the extremities. Although the exact mechanisms linking diabetes to nerve injury are not fully understood, prolonged exposure to elevated blood glucose levels is considered a major contributing factor.

PDN affects roughly 25% of diabetic patients in clinical settings and has a profound effect on daily functioning. Patients often experience burning pain, numbness, and abnormal sensations (paresthesias), typically following a stocking-glove pattern—beginning in the feet and hands and gradually progressing toward the upper limbs and legs.

Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook

The Chronic Pain Associated with Painful Diabetic Neuropathy market is expected to evolve over the coming years, driven by the anticipated introduction of new therapies from leading companies including AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation, and others between 2020 and 2034.

Discover how the chronic pain associated with diabetic neuropathy market is rising

Chronic Pain Associated with Painful Diabetic Neuropathy Therapies and Key Companies

• MEDI7352 (AstraZeneca)

• Ricolinostat (Regenacy Pharmaceuticals)

• SCS HF10 Technology (Nevro Corp.)

• Erchonia® EVRL™ (Erchonia Corporation), are in progress and anticipated to enter the market soon.

Scope of the Chronic Pain Associated with Painful Diabetic Neuropathy Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Chronic Pain Associated with Painful Diabetic Neuropathy Companies: AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation, and others

• Chronic Pain Associated with Painful Diabetic Neuropathy Therapeutic Assessment: Chronic Pain Associated with Painful Diabetic Neuropathy current marketed and Chronic Pain Associated with Painful Diabetic Neuropathy emerging therapies

• Chronic Pain Associated with Painful Diabetic Neuropathy Market Dynamics: Chronic Pain Associated with Painful Diabetic Neuropathy market drivers and Chronic Pain Associated with Painful Diabetic Neuropathy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Chronic Pain Associated with Painful Diabetic Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Associated with Painful Diabetic Neuropathy Market Access and Reimbursement

Request sample pages @ https://www.delveinsight.com/sample-request/chronic-pain-associated-with-painful-diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Chronic Pain Associated with Painful Diabetic Neuropathy Patient Share (%) Overview at a Glance

5. Chronic Pain Associated with Painful Diabetic Neuropathy Market Overview at a Glance

6. Chronic Pain Associated with Painful Diabetic Neuropathy Disease Background and Overview

7. Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Pain Associated with Painful Diabetic Neuropathy

9. Chronic Pain Associated with Painful Diabetic Neuropathy Current Treatment and Medical Practices

10. Unmet Needs

11. Chronic Pain Associated with Painful Diabetic Neuropathy Emerging Therapies

12. Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook

13. Country-Wise Chronic Pain Associated with Painful Diabetic Neuropathy Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Chronic Pain Associated with Painful Diabetic Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook 2034

Related Reports:

Chronic Pain Associated with Painful Diabetic Neuropathy Pipeline Insights, DelveInsight

“Chronic Pain Associated with Painful Diabetic Neuropathy Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pain Associated with Painful Diabetic Neuropathy market. A detailed picture of the Chronic Pain Associated with Painful Diabetic Neuropathy pipeline landscape is provided, which includes the disease overview and Chronic Pain Associated with Painful Diabetic Neuropathy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Pain Associated with Painful Diabetic Neuropathy Market: Epidemiology, Pipeline, Companies Working, DelveInsight | AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation

“Complex Regional Pain Syndrome Clinical Trials”

The Complex Regional Pain Syndrome (CRPS) pipeline includes over three key companies actively developing more than three treatment therapies, according to DelveInsight.

Complex Regional Pain Syndrome Overview:

Complex Regional Pain Syndrome (CRPS) is a persistent pain disorder that usually develops following trauma to a limb and can affect one or more limbs. It is categorized into Type I (without confirmed nerve injury) and Type II (with confirmed nerve damage). CRPS is recognized as a regional post-traumatic neuropathic pain condition, where the severity of symptoms often exceeds that of the initial injury. The condition affects roughly 26 individuals per 100,000, with a higher incidence in women (3.5:1) and is most commonly seen in people in their mid-thirties.

CRPS can result from a variety of injuries, including fractures, sprains, crush injuries, nerve damage, strokes, or surgical procedures, with approximately 91% of cases arising after surgery. The wrist is especially prone, particularly following distal radial fractures. The underlying cause is not fully understood but may involve immune system dysfunction, leading to nerve inflammation that disrupts blood flow, sensation, and temperature regulation.

There is no definitive test for CRPS, so diagnosis is primarily clinical and based on the Budapest Criteria. Additional assessments such as bone scans, X-rays, MRI, and specialized nerve imaging may aid in evaluating bone or nerve alterations. While there is no cure, early diagnosis and intervention are essential to managing symptoms, slowing disease progression, and enhancing patients’ quality of life.

Request for a detailed insights report on Complex Regional Pain Syndrome pipeline insights

“Complex Regional Pain Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Complex Regional Pain Syndrome Therapeutics Market.

Key Takeaways from the Complex Regional Pain Syndrome Pipeline Report

• DelveInsight’s Complex Regional Pain Syndrome (CRPS) pipeline report highlights a dynamic landscape, with more than three active companies developing over three therapeutic candidates for CRPS treatment.

• Leading companies in this space, including Takeda, Tryp Therapeutics, and Soin Therapeutics, are actively exploring novel therapies to enhance the management of CRPS. Notable pipeline candidates in various stages of development include Soticlestat, TRP-8803, and others.

• In March 2025, the North Queensland Persistent Pain Management Service was inaugurated at Townsville University Hospital. This $4.4 million center provides comprehensive care for chronic pain patients, including those with CRPS, offering both in-person and telehealth services.

• In December 2025, the U.S. FDA granted Orphan Drug Designation to BRC-002, a botanically derived oral cannabinoid therapy developed by Biopharmaceutical Research Company (BRC). BRC-002 is designed to address CRPS-related pain along with associated comorbidities such as depression, anxiety, and sleep disturbances. Its safety and efficacy are currently being evaluated in a Phase 1 investigator-initiated trial, with plans to initiate Phase 2 by the end of 2025.

Complex Regional Pain Syndrome Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Complex Regional Pain Syndrome Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complex Regional Pain Syndrome treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Complex Regional Pain Syndrome market.

Download our free sample page report on Complex Regional Pain Syndrome pipeline insights

Complex Regional Pain Syndrome Emerging Drugs

• Soticlestat: Takeda

• TRP-8803: Tryp Therapeutics

Complex Regional Pain Syndrome Companies

Approximately three or more leading companies are actively working on therapies for Complex Regional Pain Syndrome (CRPS). Among these, Takeda has the most advanced candidates, currently in Phase II clinical trials.

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Complex Regional Pain Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Complex Regional Pain Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Complex Regional Pain Syndrome Therapies and Key Companies: Complex Regional Pain Syndrome Clinical Trials and advancements

Complex Regional Pain Syndrome Pipeline Therapeutic Assessment

• Complex Regional Pain Syndrome Assessment by Product Type

• Complex Regional Pain Syndrome By Stage

• Complex Regional Pain Syndrome Assessment by Route of Administration

• Complex Regional Pain Syndrome Assessment by Molecule Type

Download Complex Regional Pain Syndrome Sample report to know in detail about the Complex Regional Pain Syndrome treatment market @ Complex Regional Pain Syndrome Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Complex Regional Pain Syndrome Current Treatment Patterns

4. Complex Regional Pain Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Complex Regional Pain Syndrome Late-Stage Products (Phase-III)

7. Complex Regional Pain Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Complex Regional Pain Syndrome Discontinued Products

13. Complex Regional Pain Syndrome Product Profiles

14. Complex Regional Pain Syndrome Key Companies

15. Complex Regional Pain Syndrome Key Products

16. Dormant and Discontinued Products

17. Complex Regional Pain Syndrome Unmet Needs

18. Complex Regional Pain Syndrome Future Perspectives

19. Complex Regional Pain Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Complex Regional Pain Syndrome Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complex Regional Pain Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Takeda, Tryp Therapeutics, Soin Therapeutics

“Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market”

DelveInsight reports that several leading companies are actively advancing therapeutic development efforts for Neuronal Ceroid-Lipofuscinoses (CLN1 disease).

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Overview:

Neuronal Ceroid-Lipofuscinoses (NCLs), including CLN1 disease, are rare inherited neurodegenerative conditions. CLN1, also referred to as Infantile NCL (INCL) or the CLN1 subtype of Batten disease, arises from mutations in the PPT1 (palmitoyl-protein thioesterase 1) gene. These mutations cause the buildup of lipopigments (lipofuscin) within neurons and other cells, ultimately leading to progressive neurological deterioration.

Request for a detailed insights report on Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline insights

DelveInsight’s “Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Neuronal Ceroid-Lipofuscinoses (CLN1 disease), historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Takeaways from the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Report

• DelveInsight’s Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline report highlights a dynamic landscape with several key players actively pursuing novel therapies for CLN1 disease.

• Leading companies such as Pfizer, Spark Therapeutics, REGENXBIO, and others are investigating innovative drug candidates aimed at improving treatment outcomes.

• In May 2019, Abeona Therapeutics secured FDA approval for its IND application to launch a Phase 1/2 clinical trial of ABO-202, an AAV9-based gene therapy developed to deliver a functional PPT1 gene to the central nervous system and peripheral organs. Subsequently, in June 2019, the FDA granted Fast Track designation to ABO-202, acknowledging its potential to meet significant unmet needs in CLN1 disease management.

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market.

Download our free sample page report on Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline insights

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Companies

Several leading companies, including Pfizer, Spark Therapeutics, REGENXBIO, and others, are actively engaged in developing therapies for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) (CRPS).

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Therapies and Key Companies: Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Clinical Trials and advancements

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Therapeutic Assessment

• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Product Type

• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) By Stage

• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Route of Administration

• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Molecule Type

Download Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Sample report to know in detail about the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment market @ Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Current Treatment Patterns

4. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Late-Stage Products (Phase-III)

7. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Discontinued Products

13. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Product Profiles

14. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Key Companies

15. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Key Products

16. Dormant and Discontinued Products

17. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Unmet Needs

18. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Future Perspectives

19. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market, Clinical Trials, Companies, Therapies, Therapies, Treatment, Pipeline Analysis | Pfizer, Spark Therapeutics, REGENXBIO